Skip to main content
# Table 3 Clinical and laboratory findings dependent on *TKTL1* expression status

TKTL1/GUS ≤ Median (n = 17) |
TKTL1/GUS > Median (n = 16) | P value | |
---|---|---|---|

Median age (n = 33): 61 years
| 63 | 59 | p = 0.89 |

Clinical tumour stage
| uN negative n = 5 (29%) | uN negative n = 5 (31%) | p = 1.0 |

uN positive n = 12 (71%) | uN positive n = 11 (69%) | ||

Pathological tumour stage (n = 32)
| ypT0N0 n = 1 | ypT0N0 n = 2 | p = 0.69 |

ypT1-2N0 n = 6 | ypT1-2N0 n = 6 | ||

ypT3-4N0 n = 6 | ypT3-4N0 n = 2 | ||

ypTanyN+ n = 4 | ypTanyN+ n = 5 | ||

CEA (median)
| 2.1 | 4.25 | p = 0.074 |

CA 19-9
| 10 | 23 | p = 0.18 |

VEGFR1 (median)
| 0.4125; n = 10 | 0.1034; n = 16 | p = 0.19 |

VEGFR2 (median)
| 0.4413; n = 16 | 0.8241; n = 16 | p = 0.11 |

Survivin (n = 30) (median)
| 6.4; n = 17 | 8.5; n = 13 | p = 0.081 |

KRASmutated (n = 14/33)
| n = 6 (35%) | n = 8 (50%) | p = 0.49 |

Loss of PTEN (n = 2/30) | n = 1/16 (6%) | n = 1/14 (7%) | p = 1.0 |

Local recurrence
| n = 0 (0%) | n = 2 (12.5%) | p = 0.22 |

Metastasis during follow up
| n = 1 (6%) | n = 9 (56%) | p = 0.0024 |

Median DFS ∞ (months)
| 39 | 23 | p = 0.017 |

Death
| n = 2 (12%) | n = 4 (25%) | p = 0.39 |

Median Survival (months)
| 39 | 26 | p = 0.26 |